Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
36.4M
-
Number of holders
-
81
-
Total 13F shares, excl. options
-
38.5M
-
Shares change
-
+391K
-
Total reported value, excl. options
-
$438M
-
Value change
-
+$4.9M
-
Number of buys
-
41
-
Number of sells
-
-28
-
Price
-
$11.37
Significant Holders of Rapport Therapeutics, Inc. - Common Stock, $0.001 par value (RAPP) as of Q2 2025
92 filings reported holding RAPP - Rapport Therapeutics, Inc. - Common Stock, $0.001 par value as of Q2 2025.
Rapport Therapeutics, Inc. - Common Stock, $0.001 par value (RAPP) has 81 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 38.5M shares
.
Largest 10 shareholders include TRV GP V, LLC (7.14M shares), FMR LLC (5.47M shares), ARCH Venture Management, LLC (3.73M shares), Cormorant Asset Management, LP (2.94M shares), Capital International Investors (2.6M shares), JOHNSON & JOHNSON (2.5M shares), Sofinnova Investments, Inc. (2M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.53M shares), GOLDMAN SACHS GROUP INC (1.24M shares), and BlackRock, Inc. (1.22M shares).
This table shows the top 81 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.